As of Thursday, March 05, Century Therapeutics, Inc.’s IPSC share price has surged by 5.97%, which has investors questioning if this is right time to sell.

In February 2026, XellSmart Pharmaceutical Co., Ltd. (XellSmart) announced that it had secured its fourth US FDA and China NMPA clearance for Phase I/II registrational clinical trial entry with its ...

2026年2月19日，日本厚生劳动省药事审议会作出一项历史性建议：对两款基于诱导多能干细胞（iPSC）的再生医疗产品给予“附条件及期限批准”。 如果后续行政程序顺利完成，它们将成为全球首批真正迈入商业化临床应用的iPSC技术。

Tenaya Therapeutics, Inc. TNYA shares are up on Thursday, reflecting a positive market response to a research collaboration agreement with Alnylam Pharmaceuticals Inc. ALNY. • Tenaya Therapeutics ...

VANCOUVER, BC and TOKYO, March 3, 2026 /PRNewswire/ - The International Society for Cell & Gene Therapy (ISCT), the translation-focused global ...

As daylight saving time gets closer and Americans get ready for clocks to "spring forward" for 2026, the time change will affect most of the U.S. — but there are two states and several territories ...

Speakers including US historian and Iranian academic set to address City Hall rally on Monday evening ...

这两款产品分别用于治疗重症心力衰竭（ReHeart）和帕金森病（Amchepri），标志着全球首个iPSC来源细胞产品获得药事审批，诺贝尔奖得主山中伸弥教授2006年的开创性研究，历经二十年终于从实验室迈入产业化阶段。

Induced pluripotent stem cell technology is a promising, rapidly evolving field with the potential to transform cell-based therapeutics across a range of disease areas that have significant unmet ...

BioLife Solutions has executed a successful turnaround by refocusing on core products and divesting non-core assets. Read ...

Platform to detect human-relevant insights for discovery and development of therapies for neurological diseases, ...

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) used its quarterly conference call to highlight a longer cash runway following recent warrant exercises, progress in manufacturing capabilities, and early ...